Roche together with Genentech (RG7880, UTTR1147A) and Generon (Promenakin, F-652) develop IL-22 agonists for the treatment of ulcerative colitis with ongoing trials also in pancreatitis, acute alcoholic hepatitis, graft versus host disease and treatment of diabetic foot ulcers (Table 1). This evidence concerns the gene IL22 and alcoholic hepatitis.